Necesito seguir una dieta estricta o un plan de ejercicio
Retatrutide is an injectable medication currently being studied for both weight management and type 2 diabetes
Fifteen DA-treated patients developed PD, with an estimated incidence rate in the RLS group of 1.3 per 10,000 patient-years in the DA-treated subgroup
"Once-weekly semaglutide 24 mg versus once-daily liraglutide 30 mg for weight management (WEGO): a multicentre, double-blind, double-dummy, randomised controlled trial." New England Journal of Medicine, Accessed July 10, 2023, Eli Lilly and Company
Information provided is educational and not a substitute for medical advice
Clinical trial participants should also notify their trial site